Please login to the form below

Not currently logged in
Email:
Password:

autoimmune conditions

This page shows the latest autoimmune conditions news and features for those working in and with pharma, biotech and healthcare.

Syncona start-up Quell Therapeutics appoints chief exec

Syncona start-up Quell Therapeutics appoints chief exec

London-based Quell Therapeutics aims to harness this suppressive capacity of Tregs to treat immune dysfunction conditions by using gene-modified cells. ... The company says it will target a range of conditions including solid organ transplant rejection,

Latest news

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... The latter is a vital service for patients with chronic

  • Taking a lean and careful approach Taking a lean and careful approach

    This fits well with our mission to tackle unmet needs. Autoimmune conditions are increasing and diabetes is at epidemic levels. ... A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide,   melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Patient Persepective: Autoimmune Disease

    Autoimmune diseases affect 1–5% of the World’s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including Crohn’s disease, a form of inflammatory bowel

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Alzheimers
Detecting Alzheimer’s ahead of a cure
A focus on promising new research...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?
Or has the digital world has replaced our brain...

Infographics